228 related articles for article (PubMed ID: 29754160)
1. Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.
Kitajima K; Nakatani K; Yamaguchi K; Nakajo M; Tani A; Ishibashi M; Hosoya K; Morita T; Kinoshita T; Kaida H; Miyoshi Y
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1661-1671. PubMed ID: 29754160
[TBL] [Abstract][Full Text] [Related]
2. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
Lian W; Liu C; Gu B; Zhang J; Lu L; Pan H; Yao Z; Wang M; Song S; Zhang Y; Yang Z
Nucl Med Commun; 2020 Mar; 41(3):280-287. PubMed ID: 32032193
[TBL] [Abstract][Full Text] [Related]
3. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
[TBL] [Abstract][Full Text] [Related]
4. Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan.
Kaida H; Kitajima K; Nakajo M; Ishibashi M; Matsunaga T; Minamimoto R; Hirata K; Nakatani K; Hung A; Hattori S; Yasuda T; Ishii K
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3666-3682. PubMed ID: 33934168
[TBL] [Abstract][Full Text] [Related]
5. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan.
Kitajima K; Kaida H; Nakatani K; Ishibashi M; Morita T; Nakajo M; Tamaki Y; Minamimoto R
Nucl Med Commun; 2020 May; 41(5):443-451. PubMed ID: 32187159
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer.
Baysal H; Serdaroglu AY; Ozemir IA; Baysal B; Gungor S; Erol CI; Ozsoy MS; Ekinci O; Alimoglu O
J Surg Res; 2022 Oct; 278():223-232. PubMed ID: 35636197
[TBL] [Abstract][Full Text] [Related]
7. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
[TBL] [Abstract][Full Text] [Related]
8. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K
Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
[TBL] [Abstract][Full Text] [Related]
10. Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0.
Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K
Nagoya J Med Sci; 2018 May; 80(2):183-197. PubMed ID: 29915436
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy.
Nakajo M; Kitajima K; Kaida H; Morita T; Minamimoto R; Ishibashi M; Yoshiura T
Clin Radiol; 2020 Jan; 75(1):79.e9-79.e18. PubMed ID: 31662200
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
15. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.
Tőkés T; Kajáry K; Szentmártoni G; Lengyel Z; Györke T; Torgyík L; Somlai K; Tőkés AM; Kulka J; Dank M
Breast Cancer; 2017 Jan; 24(1):137-146. PubMed ID: 26979062
[TBL] [Abstract][Full Text] [Related]
17. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
18. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
19. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
20. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]